Physician profile
Barry Keith Lance
NPI 1316913577
$2,400.00
in general payments reported to CMS, 2019-2025
26 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $214 · 2021: $364 · 2022: $434 · 2023: $510 · 2024: $313 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.53 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $789.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $376.31 | 2020-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $149.28 | 2020-2025 | Korlym |
| Mannkind Corporation | $139.82 | 2021-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $111.97 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $87.88 | 2022-2025 | Gvoke Hypopen |
| Shire North American Group INC | $79.57 | 2019 | |
| Amarin Pharma, INC. | $70.34 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $68.05 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $58.05 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $55.91 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $48.41 | 2020-2021 | |
| Abbott Laboratories | $46.94 | 2020-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.44 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $33.85 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $31.80 | 2025 | Rezdiffra |
| Amgen INC. | $25.02 | 2025 | Repatha |
| Paratek Pharmaceuticals, INC. | $24.12 | 2025 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $23.27 | 2023 | Strensiq |
| Ascensia Diabetes Care US INC. | $17.57 | 2023 | |
| Abbvie INC. | $17.28 | 2023 | |
| Beta Bionics, INC. | $16.77 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amneal Pharmaceuticals LLC | $13.61 | 2019 | |
| Horizon Therapeutics Plc | $12.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Lance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.